source
- Human‑centric testing methods promise safer, cheaper drug development but repeatability remains a key obstacleRegulators such as the FDA, EMA and ICH are urging drug developers to replace animal safety studies with New Approach Methodologies that use human‑relevant models. Early research shows these models…
- Immunovant halts cutaneous lupus program after phase 2 failureImmunovant announced it is discontinuing development of its anti-FcRn antibody IMVT-1402 for cutaneous lupus erythematosus. The decision follows a mid-phase trial that did not meet its primary end…